DIAMOND trial: Patiromer for management of hyperkalemia in HFrEF

DIAMOND trial: Patiromer for management of hyperkalemia in HFrEF Patiromer is a nonabsorbed potassium binder used in the treatment of hyperkalemia. Earlier it was tested in patients with chronic kidney disease who were receiving inhibitors of the renin-angiotensin-aldosterone system (RAAS). It was found that patiromer treatment was associated with a decrease in serum potassium levels compared to placebo and a reduction in the recurrence of hyperkalemia  [1]. DIAMOND trial was designed to evaluate patiromer for the management of hyperkalemia in patients receiving RAAS inhibitors for heart failure with reduced ejection fraction (HFrEF) [2]. 1195 patients with RAAS inhibitor related current or previous hyperkalemia were enrolled in the 12 week run-in phase with patiromer and optimization of RAAS inhibitor therapy. Aim was to achieve recommended dose of angiotensin converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor, and 50 mg of mineralocorticoid receptor antagonist spironolactone or eplerenone. 878 patients who achieved the target doses of RAAS inhibitor therapy were randomized to either patiromer or placebo in a double blind pattern [3]. Primary endpoint was the mean difference in serum potassium from randomization between patiromer and placebo arms. Secondary endpoints specified were hyperkalemic events with serum potassium value above 5.5 mEq/L, durable enablement of MRA at target dose, investigator reported adverse events ...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: General Cardiology Source Type: blogs